Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 8/20 | 0.35 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.35 |
| ▸ | CTSA | P10619 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.34 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.34 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.34 |
| ▸ | SCN1A | P35498 | 1/20 | 0.34 |
| ▸ | SCN4A | P35499 | 1/20 | 0.34 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.34 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.34 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.34 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.34 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.34 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.34 |
| ▸ | AXL | P30530 | 1/20 | 0.34 |
| ▸ | MERTK | Q12866 | 1/20 | 0.34 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27710027 | 0.82 | CYP1A2 (0.36) | POLBMAPTSCN9ASLC22A12CTSA | |
| SCHEMBL4936979 | 0.75 | NPC1 (0.43) | POLBMAPTLMNASMN1; SMN2 | |
| SCHEMBL12093567 | 0.74 | LMNA (0.38) | MAPTSCN9AMAPK1CYP2C9LMNA | |
| SCHEMBL12089821 | 0.72 | SMN1; SMN2 (0.39) | MAPTMAPK1CYP2C9LMNATSHR | |
| SCHEMBL26168167 | 0.71 | CYP2C9 (0.41) | SCN9ASLC22A12MAPK1CYP2C9LMNA | |
| SCHEMBL16044967 | 0.71 | CTSA (0.42) | CTSAMAPK1 | |
| SCHEMBL4924580 | 0.68 | VNN1 (0.47) | SCN9ACTSASCN5ALMNASMN1; SMN2 | |
| SCHEMBL15577599 | 0.67 | NR3C1 (0.39) | MAPK1 | |
| SCHEMBL15157769 | 0.66 | LMNA (0.34) | CYP2C9LMNATSHRAPEX1SMN1; SMN2 | |
| SCHEMBL4914995 | 0.66 | NPSR1 (0.39) | SCN9ASLC22A12CTSASCN5AAXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080306055-A1 | Heterocyclic Mchr1 Antagonists And Their Use In Therapy | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | US | disclosed |
| EP-1831194-A1 | HETEROCYCLIC MCHr1 ANTAGONISTS AND THEIR USE IN THERAPY | AstraZeneca AB (SE) | 2007-09-12 | — | — | EP | disclosed |
| WO-2006068594-A1 | HETEROCYCLIC MCHr1 ANTAGONISTS AND THEIR USE IN THERAPY | ASTRAZENECA AB (SE) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306055-A1 | Heterocyclic Mchr1 Antagonists And Their Use In Therapy | MCHR1, MCHR2, MC1R | POLB 3929/4885MAPT 212/4885SCN9A 1164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.